- Nurix Therapeutics ( NASDAQ: NRIX ) on Thursday said the U.S. FDA had approved its investigational new drug application to expand its ongoing phase 1 trial of its inhibitor NX-1607 into sites in the U.S.
- NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types.
- The early stage trial is currently enrolling patients in the UK.
- "We look forward to sharing initial biomarker data from the Phase 1 trial at an appropriate medical meeting in the second half of 2022,” said NRIX's executive VP of clinical development Robert Brown.
- NRIX stock closed 7.8% higher at $12.51 on Wednesday.
For further details see:
FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.